Literature DB >> 19101986

Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells.

Vinita Singh-Gupta1, Hao Zhang, Sanjeev Banerjee, Dejuan Kong, Julian J Raffoul, Fazlul H Sarkar, Gilda G Hillman.   

Abstract

We previously showed that treatment of prostate cancer cells with soy isoflavones and radiation resulted in greater cell killing in vitro, and caused downregulation of NF-kappaB and APE1/Ref-1. APE1/Ref-1 functions as a redox activator of transcription factors, including NF-kappaB and HIF-1alpha. These molecules are upregulated by radiation and implicated in radioresistance of cancer cells. We extended our studies to investigate the role of HIF-1alpha survival pathway and its upstream Src and STAT3 molecules in isoflavones and radiation interaction. Radiation induced phosphorylation of Src and STAT3 leading to induction of HIF-1alpha. Genistein, daidzein or a mixture of soy isoflavones did not activate this pathway. These data were observed both in PC-3 (AR-) and C4-2B (AR+) androgen-independent cell lines. Pretreatment with isoflavones inhibited Src/STAT3/HIF-1alpha activation by radiation and nuclear translocation of HIF-1alpha. These findings correlated with decreased expression of APE1/Ref-1 and DNA binding activity of HIF-1alpha and NF-kappaB. In APE1/Ref-1 cDNA transfected cells, radiation caused a greater increase in HIF-1alpha and NF-kappaB activities but this effect was inhibited by pretreatment with soy prior to radiation. Transfection experiments indicate that APE1/Ref-1 inhibition by isoflavones impairs the radiation-induced transcription activity of NF-kappaB and HIF-1alpha. This mechanism could result in the inhibition of genes essential for tumor growth and angiogenesis, as demonstrated by inhibition of VEGF production and HUVECs tube formation. Our novel findings suggest that the increased responsiveness to radiation mediated by soy isoflavones could be due to pleiotropic effects of isoflavones blocking cell survival pathways induced by radiation including Src/STAT3/HIF-1alpha, APE1/Ref-1 and NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19101986      PMCID: PMC2670478          DOI: 10.1002/ijc.24015

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

Review 1.  Regulation of angiogenesis by hypoxia: role of the HIF system.

Authors:  Christopher W Pugh; Peter J Ratcliffe
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

Review 2.  Molecular effects of the isoflavonoid genistein in prostate cancer.

Authors:  Jasmin Bektic; Roman Guggenberger; Iris E Eder; Alexandre E Pelzer; Andreas P Berger; Georg Bartsch; Helmut Klocker
Journal:  Clin Prostate Cancer       Date:  2005-09

Review 3.  Using chemopreventive agents to enhance the efficacy of cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

4.  Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer.

Authors:  M R Kelley; L Cheng; R Foster; R Tritt; J Jiang; J Broshears; M Koch
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

5.  HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

Authors:  Michael J Gray; Jing Zhang; Lee M Ellis; Gregg L Semenza; Douglas B Evans; Stephanie S Watowich; Gary E Gallick
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

6.  Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase.

Authors:  Vitaly Balan; Deborah T Leicht; Jun Zhu; Karina Balan; Alexander Kaplun; Vinita Singh-Gupta; Jun Qin; Hong Ruan; Michael J Comb; Guri Tzivion
Journal:  Mol Biol Cell       Date:  2006-01-11       Impact factor: 4.138

7.  Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.

Authors:  Sanjeev Shukla; Gregory T MacLennan; Pingfu Fu; Jigar Patel; Susan R Marengo; Martin I Resnick; Sanjay Gupta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 8.  The hypoxic tumour microenvironment and metastatic progression.

Authors:  Patrick Subarsky; Richard P Hill
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 9.  NF-kappaB in cancer: a marked target.

Authors:  Anning Lin; Michael Karin
Journal:  Semin Cancer Biol       Date:  2003-04       Impact factor: 15.707

10.  Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest.

Authors:  Julian J Raffoul; Yu Wang; Omer Kucuk; Jeffrey D Forman; Fazlul H Sarkar; Gilda G Hillman
Journal:  BMC Cancer       Date:  2006-04-26       Impact factor: 4.430

View more
  39 in total

1.  Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer.

Authors:  Iftekhar U Ahmad; Jeffrey D Forman; Fazlul H Sarkar; Gilda G Hillman; Elisabeth Heath; Ulka Vaishampayan; Michael L Cher; Fundagul Andic; Peter J Rossi; Omer Kucuk
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury.

Authors:  Gilda G Hillman; Vinita Singh-Gupta; Lindsay Runyan; Christopher K Yunker; Joseph T Rakowski; Fazlul H Sarkar; Steven Miller; Shirish M Gadgeel; Seema Sethi; Michael C Joiner; Andre A Konski
Journal:  Radiother Oncol       Date:  2011-11-11       Impact factor: 6.280

Review 3.  APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1.

Authors:  Mark R Kelley; Millie M Georgiadis; Melissa L Fishel
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

4.  Differential effect of soy isoflavones in enhancing high intensity radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinoma.

Authors:  Gilda G Hillman; Vinita Singh-Gupta; David J Hoogstra; Lisa Abernathy; Joseph Rakowski; Christopher K Yunker; Shoshana E Rothstein; Fazlul H Sarkar; Shirish Gadgeel; Andre A Konski; Fulvio Lonardo; Michael C Joiner
Journal:  Radiother Oncol       Date:  2013-09-07       Impact factor: 6.280

Review 5.  Effects of irradiation on tumor cell survival, invasion and angiogenesis.

Authors:  Odysseas Kargiotis; Aliki Geka; Jasti S Rao; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

6.  The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α.

Authors:  Haiquan Lu; Ke Liang; Yang Lu; Zhen Fan
Journal:  Cancer Lett       Date:  2012-02-17       Impact factor: 8.679

Review 7.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

8.  B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer.

Authors:  Vinita Singh-Gupta; Sanjeev Banerjee; Christopher K Yunker; Joseph T Rakowski; Michael C Joiner; Andre A Konski; Fazlul H Sarkar; Gilda G Hillman
Journal:  Cancer Lett       Date:  2011-12-09       Impact factor: 8.679

9.  Radioprotection of lung tissue by soy isoflavones.

Authors:  Gilda G Hillman; Vinita Singh-Gupta; Fulvio Lonardo; David J Hoogstra; Lisa M Abernathy; Christopher K Yunker; Shoshana E Rothstein; Joseph Rakowski; Fazlul H Sarkar; Shirish Gadgeel; Andre A Konski; Michael C Joiner
Journal:  J Thorac Oncol       Date:  2013-11       Impact factor: 15.609

Review 10.  Herbal nutraceuticals: safe and potent therapeutics to battle tumor hypoxia.

Authors:  Devarajan Nalini; Jayaraman Selvaraj; Ganesan Senthil Kumar
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-13       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.